- Home
- MAIA vs ALGS Comparison
MAIA vs ALGS Comparison
Compare MAIA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | ALGS |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 57.2M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAIA | ALGS |
|---|---|---|
| Price | $1.37 | $13.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 873.7K | 81.5K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $3.76 |
| 52 Week High | $2.74 | $46.80 |
Technical Indicators
Market Signals| Indicator | MAIA | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 80.94 |
| Support Level | $1.07 | $9.10 |
| Resistance Level | $1.25 | $10.45 |
| Average True Range (ATR) | 0.16 | 0.75 |
| MACD | 0.06 | 0.38 |
| Stochastic Oscillator | 54.41 | 92.29 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.